We first tested the cell-surface induction of CD107a (LAMP1) in all patients, which reflects NK-cell degranulation capacity when triggered by the prototypical K562 tumor cell line or antibody-coated target cells (referred to as antibody-dependent cell cytotoxicity [ADCC] conditions thereafter) (Figure 2A). Here, LAMP1 is linked to neoplasm.